Search Results 2101-2110 of 20127 for Receptor

1. A Trial to Assess Effectiveness and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET - Mayo Clinic

   - At least 1 measurable, somatostatin receptor-positive lesion according to RECIST 1.1 determined by multiphasic CT or MRI (performed within 28 days before ...

2. Mayo Clinic Health Letter: Highlights from the January 2015 Issue

   Effective new treatments have been developed to treat high blood pressure. They include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor ...

3. A Study Of NT-175 In Adult Subjects With Unresectable, Advanced, And/or Metastatic Solid Tumors That Are Positive For HLA-A*02:01 And The TP53 R175H Mutation - Mayo Clinic

   Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 ...

4. Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza - Mayo Clinic

   ... receptor binding and antigenicity. Unlike the human H3 influenza virus strains, the equine virus isolates have no close relatives in other species and ...

5. Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients - Mayo Clinic

   ... receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory ...

6. A Study To Evaluate Intravenous Iloprost In Subjects With Symptomatic Raynaud's Phenomenon Secondary To Systemic Sclerosis - Mayo Clinic

   Subjects who have taken or are currently taking any parenteral, inhaled, or oral prostacyclin or prostacyclin receptor agonists (e.g., epoprostenol ...

7. A Study to Evaluate Lasofoxifene versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer Patients with an ESR1 Mutation - Mayo Clinic

   ... receptor positive (ER+)/human epidermal growth factor 2 negative (HER2−) breast cancer with an ESR1 mutation. Participation eligibility. Participant ...

8. Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) - Mayo Clinic

   ... receptor (CAR)-T cell therapy; Has been previously treated with a CDK inhibitor; Has a known history of Human Immunodeficiency Virus (HIV) infection; Has a ...

9. A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes (2IQP) - Mayo Clinic

   If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications, dose has been ...

10. Quantifying neuroimaging: A revolution in patient care - Mayo Clinic

    Mayo Clinic specialists apply innovative neuroimaging techniques and quantifiable machine learning methodology for individualized prognosis and treatment of ...